Additional MCL-1 specific inhibitors, including AMG 176 and AZD5991, were described in 2018 and shown to be efficacious at reducing tumor burden in murine models [17,18] and are in clinical trials for lymphoma, multiple myeloma (MM), and acute myeloid leukemia (AML) [62]. This evidence concerns the gene MCL1 and lymphoma.